Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82


In vivo alterations in calcium buffering capacity in transgenic mouse model of synucleinopathy.

Reznichenko L, Cheng Q, Nizar K, Gratiy SL, Saisan PA, Rockenstein EM, González T, Patrick C, Spencer B, Desplats P, Dale AM, Devor A, Masliah E.

J Neurosci. 2012 Jul 18;32(29):9992-8. doi: 10.1523/JNEUROSCI.1270-12.2012.


Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy.

Crews L, Spencer B, Desplats P, Patrick C, Paulino A, Rockenstein E, Hansen L, Adame A, Galasko D, Masliah E.

PLoS One. 2010 Feb 19;5(2):e9313. doi: 10.1371/journal.pone.0009313.


Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo.

Rockenstein E, Nuber S, Overk CR, Ubhi K, Mante M, Patrick C, Adame A, Trejo-Morales M, Gerez J, Picotti P, Jensen PH, Campioni S, Riek R, Winkler J, Gage FH, Winner B, Masliah E.

Brain. 2014 May;137(Pt 5):1496-513. doi: 10.1093/brain/awu057. Epub 2014 Mar 24.


Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy.

Ubhi K, Inglis C, Mante M, Patrick C, Adame A, Spencer B, Rockenstein E, May V, Winkler J, Masliah E.

Exp Neurol. 2012 Apr;234(2):405-16. doi: 10.1016/j.expneurol.2012.01.008. Epub 2012 Jan 16.


Differential calcium alterations in animal models of neurodegenerative disease: Reversal by FK506.

Overk CR, Rockenstein E, Florio J, Cheng Q, Masliah E.

Neuroscience. 2015 Dec 3;310:549-60. doi: 10.1016/j.neuroscience.2015.08.068. Epub 2015 Sep 2.


Synphilin-1 attenuates neuronal degeneration in the A53T alpha-synuclein transgenic mouse model.

Smith WW, Liu Z, Liang Y, Masuda N, Swing DA, Jenkins NA, Copeland NG, Troncoso JC, Pletnikov M, Dawson TM, Martin LJ, Moran TH, Lee MK, Borchelt DR, Ross CA.

Hum Mol Genet. 2010 Jun 1;19(11):2087-98. doi: 10.1093/hmg/ddq086. Epub 2010 Feb 25.


Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases.

Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, Adame A, Wyss-Coray T, Masliah E.

J Neurosci. 2009 Oct 28;29(43):13578-88. doi: 10.1523/JNEUROSCI.4390-09.2009.


Diet-induced obesity accelerates the onset of terminal phenotypes in α-synuclein transgenic mice.

Rotermund C, Truckenmüller FM, Schell H, Kahle PJ.

J Neurochem. 2014 Dec;131(6):848-58. doi: 10.1111/jnc.12813. Epub 2014 Aug 11.


Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors.

Ubhi K, Rockenstein E, Mante M, Inglis C, Adame A, Patrick C, Whitney K, Masliah E.

J Neurosci. 2010 May 5;30(18):6236-46. doi: 10.1523/JNEUROSCI.0567-10.2010.


Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.

Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, Xie C, Long CX, Yang WJ, Ding J, Chen ZZ, Gallant PE, Tao-Cheng JH, Rudow G, Troncoso JC, Liu Z, Li Z, Cai H.

Neuron. 2009 Dec 24;64(6):807-27. doi: 10.1016/j.neuron.2009.11.006.


Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.

Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM.

Neuron. 2002 May 16;34(4):521-33.


Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injury.

Ulusoy A, Musgrove RE, Rusconi R, Klinkenberg M, Helwig M, Schneider A, Di Monte DA.

Acta Neuropathol Commun. 2015 Mar 24;3:13. doi: 10.1186/s40478-015-0198-y.


ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo.

Spencer B, Emadi S, Desplats P, Eleuteri S, Michael S, Kosberg K, Shen J, Rockenstein E, Patrick C, Adame A, Gonzalez T, Sierks M, Masliah E.

Mol Ther. 2014 Oct;22(10):1753-67. doi: 10.1038/mt.2014.129. Epub 2014 Jul 10.


Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy.

Stefanova N, Kaufmann WA, Humpel C, Poewe W, Wenning GK.

Acta Neuropathol. 2012 Jul;124(1):51-65. doi: 10.1007/s00401-012-0977-5. Epub 2012 Apr 11.


Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.

Price DL, Rockenstein E, Ubhi K, Phung V, MacLean-Lewis N, Askay D, Cartier A, Spencer B, Patrick C, Desplats P, Ellisman MH, Masliah E.

PLoS One. 2010 Nov 16;5(11):e14020. doi: 10.1371/journal.pone.0014020.


Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.

Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA, Price DL, Lee MK.

J Neurosci. 2006 Jan 4;26(1):41-50.


Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice.

Schell H, Hasegawa T, Neumann M, Kahle PJ.

Neuroscience. 2009 Jun 2;160(4):796-804. doi: 10.1016/j.neuroscience.2009.03.002. Epub 2009 Mar 9.


alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.

Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10813-8. Epub 2002 Jul 16.


Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice.

Gu XL, Long CX, Sun L, Xie C, Lin X, Cai H.

Mol Brain. 2010 Apr 21;3:12. doi: 10.1186/1756-6606-3-12.


Gamma-synucleinopathy: neurodegeneration associated with overexpression of the mouse protein.

Ninkina N, Peters O, Millership S, Salem H, van der Putten H, Buchman VL.

Hum Mol Genet. 2009 May 15;18(10):1779-94. doi: 10.1093/hmg/ddp090. Epub 2009 Feb 26.

Supplemental Content

Support Center